Adenylate cyclase 9/AC9/ADCY9 CRISPR/Cas9 KO Plasmid (h): sc-406817

Overview

ADCY9 encodes adenylate cyclase 9 (AC9), a membrane-associated enzyme that converts ATP to cyclic AMP (cAMP), providing a core second-messenger input to GPCR-driven signaling. AC9-dependent cAMP dynamics regulate PKA- and EPAC-mediated phosphorylation networks that shape transcriptional programs, ion channel activity, and cell-type-specific responses such as metabolic regulation and inflammatory signaling. As part of the adenylyl cyclase family, AC9 contributes to compartmentalized cAMP microdomains that influence receptor desensitization and feedback control of signaling cascades. Dysregulation of cAMP pathways is implicated in cardiometabolic, neurobiological, and immune-related disease mechanisms, making ADCY9 a useful target for pathway mapping and genotype–phenotype studies.

Adenylate cyclase 9/AC9/ADCY9 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the ADCY9 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the ADCY9 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the ADCY9 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Adenylate cyclase 9/AC9/ADCY9 protein expression.

This CRISPR knockout system enables efficient generation of ADCY9-deficient cell models for investigation of Adenylate cyclase 9/AC9/ADCY9 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

Key Features

• sgRNAs targeting ADCY9 exon(s) critical for Adenylate cyclase 9/AC9/ADCY9 function
• Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
• GFP reporter for identification of transfected cells
• Pool of plasmids targeting multiple ADCY9 genomic sites to improve knockout efficiency
• Compatible with delivery by transfection

Design Variants

CRISPRs +/- HDRs

• gRNAs encoded by Adenylate cyclase 9/AC9/ADCY9 CRISPR/Cas9 KO Plasmid (h) and Adenylate cyclase 9/AC9/ADCY9 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the ADCY9 locus. One or both targeting designs may be available. See Related Products for availability.
• HDR donor constructs encoded by Adenylate cyclase 9/AC9/ADCY9 HDR Plasmid (h) and Adenylate cyclase 9/AC9/ADCY9 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by ADCY9 homology arms to support homology-directed repair at defined ADCY9 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.